key: cord-0890818-zvye4931
authors: Kuroda, Naoto
title: Estimated effect of COVID-19 vaccine in people with epilepsy
date: 2021-05-19
journal: Epilepsy Behav
DOI: 10.1016/j.yebeh.2021.108072
sha: e4d42afbab8648647fa1535705fbf97a807e9fed
doc_id: 890818
cord_uid: zvye4931

nan

To the editor, Coronavirus disease 2019 (COVID-19) is a novel infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This disease represents one of the most significant pandemics in human history. [1] Vaccine has recently been developed [2] [3] [4] and is being administered in some countries, but its widespread use is not yet sufficient. The distribution strategy should consider estimated effects of the vaccine.

Herein, we assess the estimated effect of the COVID-19 vaccine in patients with epilepsy.

First, we modeled the number needed to vaccinate (NNV) to prevent one COVID-19-related death in patients with epilepsy. To calculate NNV in the general population [5] :

Risk of catching and dying from COVID-19 in a given period was calculated using QCOVID (https://qcovid.org/; Copyright © 2020, University of Oxford). [6] Based on this NNV model, we created several scenarios, as shown in Table 1 .

As based on the database of England [6] ; however, the infection rates differed greatly by region/community. [5] Third, we should note that the absolute risks presented, however, will change over time in line with the prevailing SARS-C0V-2 infection rate and the extent of compliance with infection prevention policies, such as social distancing. This is discussed as a limitation in the article of QCOVID. [6] Forth, this model did not consider the impact of the vaccine's side effects. Finally, in the field of epilepsy, where there are many pediatric patients, the fact that the vaccine was not currently approved for use in children under the age of 16 was another limitation. [2] [3] [4] In conclusion, we have discussed the importance of estimating the effect of the COVID-19 vaccine on people with epilepsy to maximize the effect of the vaccine in the field of epilepsy.

This work did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

None 

None Highlight  COVID-19 vaccine has recently been developed.

 We assess the estimated effect of COVID-19 vaccine in patients with epilepsy.

 We modeled the number needed to vaccinate to prevent one death.

 We discussed the importance of COVID-19 vaccine for the patients with epilepsy.

Clinical characteristics of coronavirus disease 2019 in China

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study

Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study

Incidence and case fatality rate of COVID-19 in patients with active epilepsy

None Naoto Kuroda 5 Naoto Kuroda 6